Zepbound for Sleep Apnea
The First FDA-Approved Drug Treatment

Why Sleep Apnea Is Undertreated

Obstructive sleep apnea (OSA) affects an estimated 30 million Americans, with most undiagnosed or inadequately treated. The standard treatment — CPAP (continuous positive airway pressure) — is effective when used consistently, but roughly 50% of patients do not use it regularly enough to achieve benefit.

Obesity drives OSA through multiple mechanisms: excess adipose tissue narrows the airway, and fat deposits in the chest restrict respiratory movement. Before Zepbound, treatment options for CPAP-intolerant patients with obesity were limited.

The SURMOUNT-OSA Trial

The FDA approval was based on phase 3 SURMOUNT-OSA, published in NEJM. The trial enrolled 469 adults with moderate-to-severe OSA and obesity.

Results:

• AHI (apnea-hypopnea index) reduction: 20-24 events/hour greater than placebo
• Up to 50% of patients no longer met criteria for OSA after one year
• Average weight loss: ~18% of body weight (~45 lbs)
• Patients on CPAP were more likely to discontinue CPAP (no longer needed it)

Who Qualifies for Zepbound's OSA Indication

Adults with:

• Moderate-to-severe obstructive sleep apnea (confirmed by sleep study)
• Obesity (BMI ≥30)
• Cannot tolerate CPAP OR already on CPAP and want to address root cause

Cost

Through LillyDirect:

• $299–449/mo depending on dose and insurance
• Some payers now cover Zepbound when OSA is documented (higher coverage rate than for obesity-only indication)

Medical disclaimer: Educational content, not medical advice. Consult a physician before starting any prescription medication. Page medically reviewed by Teja V. Surapaneni, MD, MS — Board-Certified Internal Medicine (NV, WA, OR, WI). Last reviewed: May 2026.